EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSTRUG00000014871
Gene Symbol: NR3C2
4 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSTRUG00000008459
Gene Symbol: NOD2
2 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSTRUG00000007104
Gene Symbol: OPRK1
1 Cross references
197 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSTRUG00000028878
Gene Symbol: OPRL1
3 Cross references
189 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSTRUG00000007606
Gene Symbol: OXTR
1 Cross references
183 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSTRUG00000008318
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSTRUG00000013866
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSTRUG00000016146
Gene Symbol: PPARD
4 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSTRUG00000015522
Gene Symbol: PPARG
2 Cross references
386 Possible Orthologues:

Peroxisome Proliferators-Activated Receptor Alpha1

Ensembl ID : ENSTRUG00000016463
Gene Symbol: PPARA1
4 Cross references
396 Possible Orthologues:

Peroxisome Proliferators-Activated Receptor Alpha2

Ensembl ID : ENSTRUG00000005904
Gene Symbol: PPARA2
2 Cross references
383 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSTRUG00000007584
Gene Symbol: LOC101062512
4 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).